tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Nurix Therapeutics Announces Leadership Change in Committee

Story Highlights
Nurix Therapeutics Announces Leadership Change in Committee

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Nurix Therapeutics ( (NRIX) ) has provided an announcement.

On August 19, 2025, Nurix Therapeutics announced that Lori A. Kunkel, M.D., would resign from her position as a Class III director and chair of the Clinical and Commercialization Committee, effective September 1, 2025. Her resignation was not due to any disagreements with the company. In response, the board appointed Roy D. Baynes to take over as chair of the Clinical and Commercialization Committee, also effective September 1, 2025.

The most recent analyst rating on (NRIX) stock is a Hold with a $9.50 price target. To see the full list of analyst forecasts on Nurix Therapeutics stock, see the NRIX Stock Forecast page.

Spark’s Take on NRIX Stock

According to Spark, TipRanks’ AI Analyst, NRIX is a Neutral.

Nurix Therapeutics faces significant financial and technical challenges, with ongoing losses and bearish market trends. However, the positive clinical trial results offer a potential catalyst for future growth. The company’s focus on improving operational efficiency and profitability will be crucial for long-term success.

To see Spark’s full report on NRIX stock, click here.

More about Nurix Therapeutics

Average Trading Volume: 849,176

Technical Sentiment Signal: Sell

Current Market Cap: $752.3M

See more insights into NRIX stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1